The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Zhuravleva M.V.

I.M. Sechenov First Moscow State Medical University (Sechenov University);
Scientific Centre of Medical Application Expertise of the Ministry of the Healthcare of the Russian Federation

Bessemeltsev S.S.

Russian Research Institute of Hematology and Transfusiology

Khimich T.V.

Sechenov First Moscow State Medical University

Gagarina Yu.V.

Sechenov First Moscow State Medical University

Comparative pharmacoeconomic analysis of romiplostim and eltrombopag for the chronic idiopathic thrombocytopenic purpura in Russian Federation

Authors:

Zhuravleva M.V., Bessemeltsev S.S., Khimich T.V., Gagarina Yu.V.

More about the authors

Journal: Medical Technologies. Assessment and Choice. 2022;44(2): 52‑61

DOI: 10.17116/medtech20224402152

Read: 1970 times

Download PDF (RU)
Contact the author
Table of contents

COMPARATIVE PHARMACOECONOMIC ANALYSIS OF ROMIPLOSTIM AND ELTROMBOPAG FOR THE CHRONIC IDIOPATHIC THROMBOCYTOPENIC PURPURA IN RUSSIAN FEDERATION
COMPARATIVE PHARMACOECONOMIC ANALYSIS OF ROMIPLOSTIM AND ELTROMBOPAG FOR THE CHRONIC IDIOPATHIC THROMBOCYTOPENIC PURPURA IN RUSSIAN FEDERATION

To cite this article:

Zhuravleva MV, Bessemeltsev SS, Khimich TV, Gagarina YuV. Comparative pharmacoeconomic analysis of romiplostim and eltrombopag for the chronic idiopathic thrombocytopenic purpura in Russian Federation. Medical Technologies. Assessment and Choice. 2022;44(2):52‑61. (In Russ.)
https://doi.org/10.17116/medtech20224402152

Подписка 2026 Медицинские технологии. Оценка и выбор (Medical Technologies. Assessment and Choice)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Is arti­ficial inte­lligence nece­ssary for healthcare system?. Medi­cal Technologies. Asse­ssment and Choice. 2024;(4):40-48
Cost-effectiveness analysis of deno­sumab therapy in adults with solid tumors and bone meta­stases (in Russian healthcare). Medi­cal Technologies. Asse­ssment and Choice. 2024;(4):74-89
Economic issues of medi­cal care for hype­rparathyroidism. Part 1. Primary hype­rparathyroidism. Medi­cal Technologies. Asse­ssment and Choice. 2025;(1):51-61
Cost-effectiveness analysis of bariatric surgery in obese patients. Medi­cal Technologies. Asse­ssment and Choice. 2025;(1):62-75
Economics of hype­rparathyroidism. Part 2 — seco­ndary hype­rparathyroidism. Medi­cal Technologies. Asse­ssment and Choice. 2025;(3):74-82
Abstract:

OBJECTIVE

To compare clinical and economical effectiveness of romiplostim and eltrombopag in the 2d line of treatment of chronic idiopathic thrombocytopenic purpura (ITP) and to perform budget impact analysis in Russian healthcare system.

MATERIAL AND METHODS

Cost-effectiveness and budget impact analysis were performed. Clinical efficacy of drugs was assessed on the base of independent indirect comparison. Treatment response was used as a criterion of efficacy. Current practice of IPT treatment was compared to complete replacement of eltrombopag to romiplostim during 3 years in budget impact analysis. The study was carried out from the Russian healthcare system point of view and took into account direct medical costs of drugs and out-patient service necessary for patients’ follow-up.

RESULTS

Cost of platelet response to treatment was 16% lower for romiplostim vs eltrombopag: 2.4 vs 2.9 million rubles. Replacement of eltrombopag with romiplostim will increase the budget expenses for 345 million rubles in the 1st year, but 193 patients will achieve treatment response additionally (+9.4%). Following replacement of eltrombopag with romiplostim up to three years will increase the budget expenses for 2d line therapy of ITP for 1.518 million rubles (10%), which results with 1.074 patients additionally responded to treatment (+17.3%).

CONCLUSION

Romiplostim is an efficient option of CITP treatment and could be recommended for routine usage in Russian healthcare system.

Keywords:

chronic idiopathic thrombocytopenic purpura
romiplostim
eltrombopag
clinico-economical analysis

Authors:

Zhuravleva M.V.

I.M. Sechenov First Moscow State Medical University (Sechenov University);
Scientific Centre of Medical Application Expertise of the Ministry of the Healthcare of the Russian Federation

Bessemeltsev S.S.

Russian Research Institute of Hematology and Transfusiology

Khimich T.V.

Sechenov First Moscow State Medical University

Gagarina Yu.V.

Sechenov First Moscow State Medical University

Received:

21.03.2022

Accepted:

07.04.2022

Close metadata

References:

  1. Klinicheskie rekomendacii. Idiopaticheskaya trombocitopenicheskaya purpura (ITP) u vzroslyh. Nacional’noe gematologicheskoe obshchestvo. Odobreny Nauchno-prakticheskim Sovetom Minzdrava Rossii. 2021. (In Russ.).
  2. Melikyan AL, Egorova EK, Pustovaya EI, Kolosheynova TI, Volodicheva EM, Kaporskaya TS, et al. Interim results of an epidemiological study of idiopathic thrombocytopenic purpura in adults in the Russian Federation. Gematologiya i transfuziologiya. 2019;64(4):436-446. (In Russ.). https://doi.org/10.35754/0234-5730-2019-64-4-436-446
  3. Kuter DJ, Bussel JB, Lyons RM, Pullarkat V, Gernsheimer TB, Senecal FM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a doubleblind randomised controlled trial. Lancet. 2008;371(9610):395-403.  https://doi.org/10.1016/S0140-6736(08)60203-2
  4. Cheng G, Saleh MN, Marcher C, Vasey S, Mayer B, Aivado M, et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet. 2011;377(9763):393-402.  https://doi.org/10.1016/S0140-6736(10)60959-2
  5. Metodicheskie rekomendacii po raschetu zatrat pri provedenii kliniko-ekonomicheskih issledovanij lekarstvennyh preparatov. FGBU «Centr ekspertizy i kontrolya kachestva medicinskoj pomoshchi» Ministerstva zdravoohraneniya Rossijskoj Federacii. M. 2017. (In Russ.). Accessed April 1, 2022. https://rosmedex.ru/wp-content/uploads/2018/02/Metodicheskie-rekomendatsii-po-raschetu-zatrat-pri-provedenii-kliniko-e%60konomicheskih-issledovaniy-lekarstvennyih-preparatov-2017.pdf
  6. Cooper K, Matcham J, Helme K, Akehurst R. Update on romiplostim and eltrombopag indirect comparison. International Journal of Technology Assessment in Health Care. 2014;30(1):129-30.  https://doi.org/10.1017/S0266462313000767
  7. Kuter DJ, Newland A, Chong BH, Rodeghiero F, Romero MT, Pabinger I, et al. Romiplostim in adult patients with newly diagnosed or persistent immune thrombocytopenia (ITP) for up to 1 year and in those with chronic ITP for more than 1 year: a subgroup analysis of integrated data from completed romiplostim studies. British Journal of Haematology. 2019;185(3):503-513.  https://doi.org/10.1111/bjh.15803
  8. Metodicheskie rekomendacii po provedeniyu sravnitel’noj kliniko-ekonomicheskoj ocenki lekarstvennogo preparata. FGBU «Centr ekspertizy i kontrolya kachestva medicinskoj pomoshchi» Ministerstva zdravoohraneniya Rossijskoj Federacii. M. 2016. (In Russ.). Accessed April 1, 2022. https://rosmedex.ru/wp-content/uploads/2016/12/MR-KE%60I-23.12.2016.pdf
  9. Zhang J, Yu KF. What’s the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. JAMA. 1998;280(19):1690-1691. https://doi.org/10.1001/jama.280.19.1690
  10. Metodicheskie rekomendacii po ocenke vliyaniya na byudzhet v ramkah realizacii programmy gosudarstvennyh garantij besplatnogo okazaniya grazhdanam medicinskoj pomoshchi. FGBU «Centr ekspertizy i kontrolya kachestva medicinskoj pomoshchi» Ministerstva zdravoohraneniya Rossijskoj Federacii. M. 2016. (In Russ.). Accessed April 1, 2022. https://rosmedex.ru/wp-content/uploads/2016/12/MR-AVB-23.12.2016.pdf
  11. Krysanov IS, Zyryanov SK, Krysanova VS. Pharmacoeconomic study of the use of thrombopoietin receptor agonists in adult patients with chronic idiopathic thrombocytopenic purpura in Russian Federation. Gematologiya i transfuziologiya. 2017;62(1):20-25. (In Russ.).
  12. Pyadushkina EA, Frolov MYu, Avksentyeva MV. Clinical and economic evaluation of thrombopoietin receptor agonists in the treatment of chronic idiopathic thrombocytopenic purpura in adults. Farmakoekonomika. Sovremennaya farmakoekonomika i farmakoepidemiologiya. 2015;8(4):50-61. (In Russ.). https://doi.org/10.17749/2070-4909.2015.8.4.050-061
  13. Pyadushkina EA, Frolov MYu, Shuvaev VA, Rogov VA. Pharmacoeconomic analysis of thrombopoietin receptor agonists in the treatment of chronic idiopathic thrombocytopenic purpura in adults. Kachestvennaya klinicheskaya praktika. 2018;(1):4-13. (In Russ.). https://doi.org/10.24411/2588-0519-2018-10033
  14. Perechen’ redkih (orfannyh) zabolevanij ot 4 marta 2021 goda i ot 23 iyunya 2021 goda. Accessed April 1, 2022. https://minzdrav.gov.ru/documents/9641-perechen-redkih-orfannyh-zabolevaniy
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.